SCHEMBL3404259

SCHEMBL3404259

CCOC(=O)CNc1ccc(OC)nc1NCC(CNC(=O)OC(C)(C)C)O[Si](C)(C)C(C)(C)C

nearest known ligand 0.33

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 1/20 0.33
PCSK9 Q8NBP7 1/20 0.33
SYK P43405 1/20 0.32
DRD2 P14416 1/20 0.31
TGFBR1 P36897 1/20 0.31
BRD4 O60885 1/20 0.31
ALDH1A1 P00352 2/20 0.30
MAPT P10636 2/20 0.30
HPGD P15428 2/20 0.30
KDM4E B2RXH2 1/20 0.30
GLA P06280 1/20 0.30
GAA P10253 1/20 0.30
HIF1A Q16665 1/20 0.30
CYP3A4 P08684 2/20 0.30
ELANE P08246 1/20 0.30
LMNA P02545 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3404254 1.00 SERPINE1 (0.33) SERPINE1PCSK9SYKDRD2TGFBR1
SCHEMBL3401324 0.82 PCSK9 (0.37) SERPINE1PCSK9SYKBRD4CYP3A4
SCHEMBL3401318 0.82 PCSK9 (0.37) SERPINE1PCSK9SYKBRD4CYP3A4
SCHEMBL3787002 0.82 BRD4 (0.42) BRD4ALDH1A1MAPTHPGDKDM4E
SCHEMBL3407462 0.80 STK17B (0.46) BRD4
SCHEMBL3846399 0.75 LMNA (0.38) ALDH1A1MAPTHPGDKDM4EGLA
SCHEMBL20995966 0.73 BTK (0.42) DRD2
SCHEMBL19707058 0.72 CRHR1 (0.39) DRD2
SCHEMBL1445679 0.71 SERPINE1 (0.45) SERPINE1PCSK9SYKKDM4EGAA
SCHEMBL14747791 0.71 ALDH1A1 (0.31) DRD2ALDH1A1MAPTHPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2254887-B9 OXAZOLIDINONE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2013-05-29 EP disclosed
US-8349826-B2 Oxazolidinone derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2013-01-08 US disclosed
EP-2254887-B1 OXAZOLIDINONE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2012-12-19 EP disclosed
US-20100331308-A1 OXAZOLIDINONE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-12-30 US disclosed
EP-2254887-A1 OXAZOLIDINONE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-12-01 EP disclosed
WO-2009104159-A1 OXAZOLIDINONE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331308-A1 OXAZOLIDINONE DERIVATIVES OXA1L, UQCRB, O60361 SERPINE1 2913/4885PCSK9 3847/4885SYK 957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.